Skip to main content

Table 1 Baseline characteristics stratified by the use of baseline metformin

From: Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin

Variables Metformin No metformin
Empagliflozin (n = 25) Placebo (n = 28) P value* Empagliflozin (n = 27) Placebo (n = 25) P value*
Age (yr) 64.6 ± 11.1 62.1 ± 10.1 0.400 66.3 ± 11.1 66.3 ± 9.3 0.983
Women 9 (36.0) 11 (39.3) 1.000 7 (25.9) 6 (24.0) 1.000
Diabetes duration (yr) 14.8 ± 10.1 12.9 ± 7.9 0.478 12.2 ± 16.2 13.2 ± 9.1 0.810
eGFR (mL/min/1.73 m2) 65.9 ± 10.9 73.0 ± 14.0 0.044 67.9 ± 13.8 65.1 ± 12.9 0.437
eGFR < 60 mL/min/1.73 m2 7 (28.0) 4 (14.3) 0.313 8 (29.6) 10 (40.0) 0.562
History
 Hypertension 20 (80.0) 19 (67.9) 0.365 21 (77.8) 17 (68.0) 0.536
 Dyslipidemia 19 (76.0) 20 (71.4) 0.763 20 (74.1) 18 (72.0) 1.000
 Cerebrovascular disease 2 (8.0) 6 (21.4) 0.256 4 (14.8) 9 (36.0) 0.112
 Cardiovascular disease 24 (96.0) 24 (85.7) 0.355 26 (96.3) 20 (80.0) 0.094
 Heart failure 12 (48.0) 12 (42.9) 0.786 11 (40.7) 7 (28.0) 0.392
Medication
 ACE inhibitor or ARB 15 (60.0) 17 (60.7) 1.000 16 (59.3) 21 (84.0) 0.068
 Beta-blocker 9 (36.0) 7 (25.0) 0.550 10 (37.0) 12 (48.0) 0.575
 Diuretic 2 (8.0) 3 (10.7) 1.000 6 (22.2) 7 (28.0) 0.752
 Statin 22 (88.0) 18 (64.3) 0.059 21 (77.8) 18 (72.0) 0.752
 Insulin 3 (12.0) 2 (7.1) 0.658 2 (7.4) 3 (12.0) 0.662
 Sulfonylurea 7 (28.0) 7 (25.0) 1.000 1 (3.7) 5 (20.0) 0.094
 Alpha-glucosidase inhibitor 4 (16.0) 6 (21.4) 0.732 4 (14.8) 2 (8.0) 0.670
 Thiazolidinedione 7 (28.0) 10 (35.7) 0.572 5 (18.5) 3 (12.0) 0.705
 DPP-4 inhibitor 17 (68.0) 19 (67.9) 1.000 20 (74.1) 17 (68.0) 0.762
  1. Data are expressed as n (%) or mean ± SD
  2. ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker, DPP-4 dipeptidyl peptidase-4, eGFR estimated glomerular filtration rate
  3. * Empagliflozin vs. placebo